AnnouncementDetails

Actions

Dr. Sulaiman Al Habib Medical Services Group announces its Interim Financial Results for the Period Ending on 2022-06-30 ( Six Months )

Element ListCurrent QuarterSimilar quarter for previous year%ChangePrevious Quarter% Change
Sales/Revenue 2,014.011,751.215.011,990.861.16
Gross Profit (Loss) 670.87551.0221.75658.561.87
Operational Profit (Loss) 414.75339.7322.08422.09-1.74
Net Profit (Loss) after Zakat and Tax 398.13325.422.35390.51.95
Total Comprehensive Income 398.91327.1221.95391.291.95
All figures are in (Millions) Saudi Arabia, Riyals
Element ListCurrent PeriodSimilar period for previous year%Change
Sales/Revenue 4,004.873,445.9916.22
Gross Profit (Loss) 1,329.441,100.4420.81
Operational Profit (Loss) 836.83689.3621.39
Net Profit (Loss) after Zakat and Tax 788.64644.422.38
Total Comprehensive Income 790.2640.0823.45
Total Share Holders Equity (after Deducting Minority Equity) 5,593.875,096.829.75
Profit (Loss) per Share 2.251.84
All figures are in (Millions) Saudi Arabia, Riyals
Element ListExplanation
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is Net Income attributable to the company’s shareholders for Q2 - 2022 increased by 22.35% to reach SAR 398.13 million as compared to SAR 325.40 million in the corresponding quarter of the previous year, which is primarily due to the following:

1. Revenues: Q2 – 2022 revenues grew by 15.01% reaching to SAR 2,014.01 million, with an increase of SAR 262.81 million as compared to SAR 1,751.20 million in the corresponding quarter of the previous year, as a result of the growth in all group segments.

Revenue growth for Q2 - 2022 was mainly driven by the growth in hospital segment, due to the increase in both numbers of patients and the increase in occupancy for inpatient beds and outpatient clinics. Pharmacy segment sales increase was driven by the increase in the number of patients as compared to the similar quarter of the previous year.

2. EBITDA for Q2 - 2022 increased by SAR 88.69 million reaching SAR 526.72 million, with an increase of 20.25% compared to the same quarter of the previous year, EBITDA margin improved to reach at 26.15% compared to 25.01% in the same quarter of the previous year.

3. Net Income for Q2 - 2022 increased by 22.35% to reach SAR 398.13 million, with an improved net income margin by 1.19% reaching 19.77% of revenue compared to 18.58% for the corresponding quarter of the previous year. Net Income increase was driven by the revenue growth due to the increase in the number of patients and the increase in occupancy for both inpatient beds and outpatient clinics.

The reason of the increase (decrease) in the net profit during the current quarter compared to the previous quarter of the current year is Net income attributable to the company’s shareholders increased by 1.95% in Q2 - 2022 compared to Q1 - 2022, which was driven by the increase in revenue of 1.16% during Q2 – 2022 mainly due to the increase in the number of patients.
The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is Net Income attributable to the company’s shareholders for the six months period ended 30th June 2022 increased by 22.38% to reach SAR 788.64 million as compared to SAR 644.40 million in the similar period of the previous year, which is primarily due to the following:

1. Revenues: for the six months period ended 30th June 2022, revenues grew by 16.22% reaching to SAR 4,004.87 million, with an increase of SAR 558.88 million as compared to SAR 3,445.99 million in the similar period of the previous year, as a result of the growth in all group segments.

Revenue growth for the six months period ended 30th June 2022 was mainly driven by the growth in the hospital segment, due to the increase in both numbers of patients and the increase in occupancy for inpatient beds and outpatient clinics. Pharmacy segment sales increase was driven by the increase in the number of patients compared to the similar period of the previous year.

2. EBITDA for the six months period ended 30th June 2022 increased by SAR 163.31 million reaching SAR 1,047.23 million, with an increase of 18.48% compared to the same period of the previous year, EBITDA margin has improved reaching to 26.15% compared to 25.65% in the same period of the previous year.

3. Net Income for the six months period ended 30th June 2022 increased by 22.38% to reach SAR 788.64 million, with an improved net income margin by 0.99% reaching 19.69% of revenue compared to 18.70% for the similar period of the previous year. Net Income increase was driven by the revenue growth due to the increase in the number of patients and the increase in occupancy for both inpatient beds and outpatient clinics.

Statement of the type of external auditor's report Unmodified conclusion
Reclassification of Comparison Items None
Attached Documents  

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.

Company Profile

Actions

Company Profile

Summary

Last Price Net Change
208.0 6.0 (+2.97%)
Value Traded (SAR) Volume Traded
55,168,351 266,127